Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

A mid-stage study for ABI-5366 will begin mid next year, while Assembly continues to assess the Phase II potential of ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

For traditional approval, CAR T therapies will need to establish superiority over current standard treatments, including ...

TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech ...

Saol Therapeutics received a complete response letter for its pyruvate dehydrogenase complex deficiency treatment a week ...

At the heart of the deal is Relation’s Lab-in-the-Loop platform, which uses AI models to improve understanding of diseases ...

What China is accomplishing in R&D “has implications for everyone playing in the R&D or innovation world,” McKinsey’s ...

GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated ...

Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...

Although still in Phase I, Wave Life Sciences’ injectable RNA weight loss treatment achieved results that impressed analysts, ...